MindWalk Holdings is trading 5.77% up at $1.10 in pre-market on November 5, 2026, with no clear overnight catalyst identified.
- The company announced a multi-year Teva Australia agreement for antibody-discovery work on November 4; financial terms were not disclosed, and available reporting does not link it directly to the gain.
- Broader market signals are mixed and do not establish a clear explanation for the move.